Kidney cancer remission rate has significantly improved over the past decade as advances in surgery, immunotherapy, and targeted therapy continue to transform outcomes for patients. Kidney cancer—most commonly renal cell carcinoma (RCC)—now offers many individuals a realistic chance of achieving remission, meaning the cancer is no longer detectable on scans or clinical evaluation. Understanding the kidney cancer remission rate, what influences it, and how it varies by stage can help patients make informed decisions during an already stressful and overwhelming time.
This article summarizes current remission rates using high-quality clinical evidence and population-level statistics.
Read About Kidney Cancer on OncoDaily
What Does Remission Mean in Kidney Cancer?
In oncology, remission means that cancer cannot be detected on imaging or physical examination. The National Cancer Institute defines remission as “a decrease in or disappearance of signs and symptoms of cancer” (NCI Dictionary of Cancer Terms, 2024).
Kidney cancer remission is assessed through CT/MRI scans, symptom review, and physical exams.
Remission Rates for Early-Stage Kidney Cancer (Stage I–II)
Most patients diagnosed early achieve long-term remission, often considered curative.
Stage I RCC
- 5-year survival rate: ~93% (National Cancer Institute SEER Program, 2024)
- Post-surgery remission rate: 85–95% (Based on recurrence rates reported in European Urology, 2019; Journal of Urology, 2018)
Stage I tumors treated with partial nephrectomy rarely return. Recurrence rates are typically 2–5% (EAU Guidelines on Renal Cell Carcinoma, 2023).
Stage II RCC
- 5-year survival rate: ~74%
- Post-surgery remission rate: 75–85%
Radical nephrectomy is often required for large tumors. Recurrence risk ranges 10–20% (EAU, NCCN 2024).
Stage III Kidney Cancer Remission Rates
Stage III involves larger tumors or spread to nearby veins or lymph nodes.
- 5-year survival rate: ~53% (SEER, 2024)
- Post-surgery remission rate: 55–65%
Patients with high-risk features benefit from adjuvant pembrolizumab, which reduced recurrence risk by 32% in the KEYNOTE-564 trial (The Lancet, 2021). Recurrence risk after treatment is significant (40–50%), making follow-up essential.
Stage IV (Metastatic) Kidney Cancer Remission Rates
Metastatic RCC used to have very low remission rates before immunotherapy. Today, remission—including complete remission—is possible.
Immunotherapy Combination Trials
The following pivotal trials have reshaped outcomes:
Nivolumab + Ipilimumab (CheckMate 214)
- Complete remission: 9–12%
- Partial remission: 42%
Durable responses lasting 3+ years (Motzer et al., New England Journal of Medicine, 2018; 5-year update NEJM, 2021)
Read About CheckMate 214 Trial on OncoDaily
Pembrolizumab + Axitinib (KEYNOTE-426)
- Complete remission: 6%
- Objective response rate (ORR): 59% (Rini et al., NEJM, 2019)
Nivolumab + Cabozantinib (CheckMate 9ER)
- ORR: 55% (Choueiri et al., NEJM, 2021)
Across these modern regimens:
- Complete remission occurs in ~8–12% of metastatic RCC patients.
- Durable remission (2+ years disease-free) occurs in 20–30%, depending on risk category.
These responses were rarely seen before immunotherapy became standard.
Can Advanced Kidney Cancer Go Into Complete Remission?
Yes—particularly with immunotherapy.
Long-term data from CheckMate 214 show that many complete responders remain cancer-free 5+ years after treatment, indicating possible functional cure (NEJM, 2021). Patients with clear cell RCC show the highest likelihood of achieving durable remission.
Factors Affecting Remission Rates
Stage at Diagnosis: SEER data clearly show stage is the strongest predictor of survival, and therefore remission.
Tumor Histology: Clear cell RCC responds best to immunotherapy. Papillary and chromophobe RCC have different molecular biology and typically lower remission rates (ASCO Educational Book, 2022).
Genetic and Molecular Features: Certain genes, such as PBRM1, may increase sensitivity to immunotherapy (Miao et al., Science, 2018).
General Health: Patients with good performance status (ECOG 0–1) have better outcomes (NCCN Guidelines, 2024).
What Is the Recurrence Rate After Treatment?
Based on EAU and NCCN surveillance data:
- Stage I: ~5% recurrence
- Stage II: 10–20% recurrence
- Stage III: 40–50% recurrence
- Stage IV: high recurrence risk but improved with immunotherapy
Because kidney cancer can recur late—even 5–10 years after treatment—long-term imaging follow-up is essential.
Is Remission the Same as a Cure?
For early-stage kidney cancer, remission is often equivalent to cure.
- Stage I: Most patients cured after surgery
- Stage II: Many patients achieve long-term remission
- Stage III: Some patients cured, but recurrence risk remains
- Stage IV: Some patients in complete remission after immunotherapy may stay disease-free for years
Clinicians avoid the word “cure” for metastatic cancer, but long-lasting remission is increasingly common.
Read About Kidney Cancer Cure Rate on OncoDaily
Monitoring Remission
Standard surveillance schedules (NCCN & EAU 2024):
- Stage I–II: CT/MRI every 6–12 months for 3–5 years
- Stage III: CT/MRI every 3–6 months for 3 years, then every 6–12 months
- Stage IV: Imaging every 2–4 months during active therapy
Follow-up is customized based on pathology and risk.
The Bottom Line
Kidney cancer remission rates have improved dramatically in the last decade.
- Early-stage disease has excellent remission rates, often above 90%.
- Stage III cancer still offers a meaningful chance of long-term remission after surgery.
- Stage IV disease can now enter partial or complete remission in a substantial number of patients due to modern immunotherapy combinations.
For patients and families, the prognosis today is far more hopeful than in the past. Continued advancements in immunotherapy, targeted therapy, and precision oncology are making durable remission increasingly achievable.
You Can Watch More on OncoDaily Youtube TV
Written by Armen Gevorgyan, MD